Emmaus Life Sciences annual revenue
2010
2011
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
Emmaus Life Sciences Revenue Growth & History (EMMA)
Emmaus Life Sciences reported $12.5M in revenue for fiscal 2025, a decrease of 25.22% from the previous fiscal year.
View full Emmaus Life Sciences company overviewEmmaus Life Sciences annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.5M | −$4.2M | −25.22% |
| 2024 | 2024-12-31 | $16.7M | −$12.9M | −43.73% |
| 2023 | 2023-12-31 | $29.6M | $11.2M | +60.94% |
| 2022 | 2022-12-31 | $18.4M | −$2.2M | −10.77% |
| 2021 | 2021-12-31 | $20.6M | −$2.6M | −11.04% |
| 2020 | 2020-12-31 | $23.2M | $415,000 | +1.82% |
| 2019 | 2019-12-31 | $22.8M | $6.3M | +38.23% |
| 2018 · Dec 31 | 2018-12-31 | $16.5M | — | — |
| 2018 · Sep 30 | 2018-09-30 | $1.3M | $1.2M | +923.74% |
| 2017 | 2017-09-30 | $128,500 | $43,400 | +51.00% |
| 2016 | 2016-09-30 | $85,100 | −$15,000 | −14.99% |
| 2015 | 2015-09-30 | $100,100 | −$35,000 | −25.91% |
| 2014 | 2014-09-30 | $135,100 | $4,200 | +3.21% |
| 2013 | 2013-09-30 | $130,900 | — | — |
| 2011 | 2011-09-30 | $745,900 | $107,400 | +16.82% |
| 2010 | 2010-09-30 | $638,500 | — | — |
Emmaus Life Sciences quarterly revenue
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.3M | $3.5M | +124.28% |
| Q1 2026 | 2026-03-31 | $2.0M | −$424,000 | −17.62% |
| Q4 2025 | 2025-12-31 | $3.9M | $560,000 | +17.01% |
| Q3 2025 | 2025-09-30 | $3.4M | −$2.1M | −38.34% |
| Q2 2025 | 2025-06-30 | $2.8M | −$2.6M | −47.61% |
| Q1 2025 | 2025-03-31 | $2.4M | −$100,000 | −3.99% |
| Q4 2024 | 2024-12-31 | $3.3M | −$3.8M | −53.42% |
| Q3 2024 | 2024-09-30 | $5.5M | $460,000 | +9.17% |
| Q2 2024 | 2024-06-30 | $5.4M | −$5.4M | −50.02% |
| Q1 2024 | 2024-03-31 | $2.5M | −$4.2M | −62.89% |
| Q4 2023 | 2023-12-31 | $7.1M | $1.1M | +19.17% |
| Q3 2023 | 2023-09-30 | $5.0M | $79,000 | +1.60% |
| Q2 2023 | 2023-06-30 | $10.8M | $6.5M | +150.97% |
| Q1 2023 | 2023-03-31 | $6.8M | $3.5M | +108.81% |
| Q4 2022 | 2022-12-31 | $5.9M | $2.9M | +96.36% |
| Q3 2022 | 2022-09-30 | $4.9M | −$827,000 | −14.34% |
| Q2 2022 | 2022-06-30 | $4.3M | −$2.2M | −33.93% |
| Q1 2022 | 2022-03-31 | $3.2M | −$2.1M | −39.38% |
| Q4 2021 | 2021-12-31 | $3.0M | −$3.2M | −51.70% |
| Q3 2021 | 2021-09-30 | $5.8M | $165,000 | +2.95% |
| Q2 2021 | 2021-06-30 | $6.5M | $2.1M | +48.83% |
| Q1 2021 | 2021-03-31 | $5.3M | −$1.6M | −23.28% |
| Q4 2020 | 2020-12-31 | $6.3M | −$540,000 | −7.95% |
| Q3 2020 | 2020-09-30 | $5.6M | −$159,000 | −2.76% |
| Q2 2020 | 2020-06-30 | $4.4M | −$1.1M | −20.63% |
| Q1 2020 | 2020-03-31 | $7.0M | $2.2M | +47.74% |
| Q4 2019 | 2019-12-31 | $6.8M | $6.4M | +1654.59% |
| Q3 2019 | 2019-09-30 | $5.8M | $878,000 | +17.98% |
| Q2 2019 | 2019-06-30 | $5.5M | $5.1M | +1302.35% |
| Q1 2019 | 2019-03-31 | $4.7M | $4.2M | +923.48% |
| Q4 2018 · Dec 31 | 2018-12-31 | $387,100 | $265,100 | +217.30% |
| Q4 2018 | 2018-09-30 | $4.9M | $4.8M | +14258.82% |
| Q3 2018 | 2018-06-30 | $391,700 | $351,300 | +869.55% |
| Q2 2018 | 2018-03-31 | $459,900 | $428,000 | +1341.69% |
| Q1 2018 | 2017-12-31 | $122,000 | $99,800 | +449.55% |
| Q4 2017 | 2017-09-30 | $34,000 | $15,400 | +82.80% |
| Q3 2017 | 2017-06-30 | $40,400 | $19,300 | +91.47% |
| Q2 2017 | 2017-03-31 | $31,900 | $11,200 | +54.11% |
| Q1 2017 | 2016-12-31 | $22,200 | −$2,500 | −10.12% |
| Q4 2016 | 2016-09-30 | $18,600 | −$6,900 | −27.06% |
| Q3 2016 | 2016-06-30 | $21,100 | −$9,900 | −31.94% |
| Q2 2016 | 2016-03-31 | $20,700 | −$200 | −0.96% |
| Q1 2016 | 2015-12-31 | $24,700 | $2,000 | +8.81% |
| Q4 2015 | 2015-09-30 | $25,500 | $800 | +3.24% |
| Q3 2015 | 2015-06-30 | $31,000 | $4,900 | +18.77% |
| Q2 2015 | 2015-03-31 | $20,900 | −$18,400 | −46.82% |
| Q1 2015 | 2014-12-31 | $22,700 | −$22,300 | −49.56% |
| Q4 2014 | 2014-09-30 | $24,700 | — | — |
| Q3 2014 | 2014-06-30 | $26,100 | — | — |
| Q2 2014 | 2014-03-31 | $39,300 | — | — |
| Q1 2014 | 2013-12-31 | $45,000 | — | — |
| Q3 2012 | 2012-06-30 | $190,800 | −$7,000 | −3.54% |
| Q2 2012 | 2012-03-31 | $214,100 | $22,300 | +11.63% |
| Q1 2012 | 2011-12-31 | $184,300 | $36,400 | +24.61% |
| Q4 2011 | 2011-09-30 | $208,400 | — | — |
| Q3 2011 | 2011-06-30 | $197,800 | $38,600 | +24.25% |
| Q2 2011 | 2011-03-31 | $191,800 | — | — |
| Q1 2011 | 2010-12-31 | $147,900 | — | — |
| Q3 2010 | 2010-06-30 | $159,200 | — | — |
Emmaus Life Sciences revenue growth trends
Over the last five reported fiscal years, revenue declined from $23.2M to $12.5M, a compound annual decline of 11.68%. Emmaus Life Sciences's latest reported quarter, Q2 2026, generated $6.3M in revenue, an increase of 124.28% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Emmaus Life Sciences source filings ↗